Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Stopping Harmful Oral Bacteria In Its Path Is Goal For Case Western Reserve Researcher
The best way to keep bacteria from doing any damage is to stop them in their tracks before they can start down their pathological road to destruction.

Washington D.C., Makes Improvements On HIV/AIDS Efforts, But More Work To Be Done, Report Finds; District Expands STD Testing Program For Students
The fifth annual report card from the Washington, D.C.,-based Appleseed Center for Law and Justice examining the district"s response to HIV gives the city "high marks for rapid testing, interagency coordination, surveillance and fighting the disease in the D.C. Jail," but finds that the city falls short in other areas, the Washington Examiner reports (Neibauer, 8/5). "The government also received above-average grades for leadership, managing grants to groups that help people with the illness, and monitoring the effectiveness of those programs," the Washington Post reports. However, "While Mayor Fenty and his administration deserve recognition for the continued support of ò€¦ numerous [HIV/AIDS Administration] initiatives, his public appearances and statements about the epidemic have fallen short of his enthusiasm for action inside the government," the report said. The report added that the district could do more to address HIV and recommended that HAA assess whether the improvements they have made are reducing the spread of the virus, according to the Post (Fears, 8/5).
News of the day
Cancer Vaccines Led To Long-Term Survival For Patients With Metastatic Melanoma, Study Shows
Hoag Memorial Hospital Presbyterian announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients" own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies.
Public Health

Medtronic Completes Enrollment In International Post-Market Study Of Resolute Drug-Eluting Stent

Medtronic, Inc. (NYSE: MDT), announced completion of enrollment in RESOLUTE International, a post-market study of its Resolute Drug-Eluting Stent (DES). One-year data from this international study, which enrolled 2,464 patients at 88 sites from 17 countries in Europe, Asia, Africa, and Latin America, are expected in the second half of 2010. "RESOLUTE International will expand our experience and understanding of the Resolute DES in the setting of standard clinical practice, which affords a degree of diversity in patient types and lesion characteristics that are typically not well represented in tightly controlled clinical trials," said Prof. Dr. Franz-Josef Neumann of the Heart Center of Bad Krozingen in Germany on behalf of his co-principal investigators, Drs. Petr Widimskç½ of the Faculty Hospital of Kralovske Vinohrady in Prague and Jorge Belardi of the Cardiovascular Institute of Buenos Aires. "Together with other data from the Resolute clinical program, we expect the findings from RESOLUTE International to help physicians make the best possible treatment decisions for the spectrum of patients they see daily." RESOLUTE International is a prospective, multicenter observational study with a composite primary endpoint of cardiac death and myocardial infarction (not clearly attributable to a nontarget vessel) at one year post-implant. It is part of the Resolute clinical program, which will enroll a total of more than 6,000 patients at hundreds of clinical research sites in more than 25 countries. The Resolute DES draws on the strengths of Medtronic"s Endeavor DES. The products share the same cobalt alloy stent platform and the potent antiproliferative drug zotarolimus. Both stents also feature highly biocompatible polymers. The Resolute DES uses the BioLinx™ polymer, Medtronic"s proprietary polymer designed specifically for use on a DES. The BioLinx polymer is designed to extend the duration of drug exposure in the vessel - an elution profile of potential relevance to patients that physicians consider to be at high risk of needing a repeat procedure - without trading off polymer biocompatibility. The Resolute DES received the CE (Conformitç© Europç©ene) mark in October 2007 and is commercially available in more than 100 countries worldwide. Approximately 100,000 patients have been treated with the Resolute DES since its international launch. Use of the Resolute DES in the United States is limited to investigational clinical trials. The Resolute DES is part of Medtronic"s broad coronary stents portfolio, which also includes the Endeavor Sprint DES and the Driver and Micro-Driver Bare-Metal Stent. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009